The chief medical officer and cofounder of Linus Health discussed how changes in voice may help serve as early indicators for late-life cognitive deficits. [WATCH TIME: 3 minutes]
The pediatric epileptologist at Cleveland Clinic provided insight on her presentation at the 2022 AAN Annual Meeting that evaluated ganaxolone in phase 3 study of patients with CDKL5 deficiency disorder. [WATCH TIME: 4 minutes]
The president of the International Neuropalliative Care Society detailed potential disease states that could benefit from neuropalliative care as well as the importance of the patient community in expanding this type of approach. [WATCH TIME: 4 minutes]
The president and chief executive officer of Mapi Pharma discussed the positive phase 2 findings of a new formulation of glatiramer acetate to treat progressive forms of MS, as well as the long-term plans for the drug. [WATCH TIME: 5 minutes]
The PMD Alliance has developed a group of 6 on-demand CME events and live panel discussions, in partnership with MedStar Georgetown University Hospital, taking place on October 23-24, 2021, developed and presented by Yasar Torres-Yaghi, MD , and Fernando Pagan, MD.
Since vaccine administration, the CDC has announced 100 preliminary cases of Guillain-Barré syndrome.
Henry Ford Health System’s investment in advanced DBS technology and its commitment to multidisciplinary care has helped them become a leading treatment center for Parkinson disease and related movement disorders.
The expert panel shares clinical pearls for treatment and management of Spinal Muscular Atrophy. O painel de especialistas compartilha recomendações valiosas para o tratamento e manejo da atrofia muscular espinhal.
In addition to his work study pimavanserin in treating dementia-related psychosis, the director of the Banner Alzheimer’s Institute commented on the potential for aducanumab in Alzheimer disease.
The professor of Molecular Neuroscience at the Edmond and Lily Safra Center for Brain Sciences provided thoughts on the comfortability of prescribing aducanumab knowing its safety profile.
The chief of Movement Disorders Division at the University of Miami Miller School of Medicine discussed some of the recent focused efforts to uncover more about Parkinson disease and what is on the horizon.
The neurologist at Mayo Clinic detailed promising diagnostic tools, including the revelation of blood tests in patients with Alzheimer disease.
The fellow of autoimmune neurology at Massachusetts General Hospital also discussed concerns of associations between multiple sclerosis and COVID-19.
The senior vice president of clinical development, drug safety, and pharmacovigilance at FibroGen provides details of the phase 3 LELANTOS trial of pamrevlumab in Duchenne muscular dystrophy.
The president of the National Headache Foundation discussed whether switching or continuing preventive medications has a benefit in patients who have chronic migraine with medication overuse. [WATCH TIME: 4 minutes]
The assistant professor of neurology at Weill Cornell Medicine discussed his future aspirations to uncover more about the beneficial effects of anticoagulants in reducing recurrent stroke. [WATCH TIME: 3 minutes]
The associate professor of psychiatry at the University of Illinois at Chicago shared the findings of her and colleagues’ work that suggest that distinct cytoarchitectural changes occur in the brain that may underlie migraine chronification. [WATCH TIME: 4 minutes]
Glenn Graham, MD, PhD; and Sharyl Martini, MD, PhD, moderate a discussion with 4 clincial experts to advance specialized clinical care, education and research for Veterans with movement disorders, multiple sclerosis, epilepsy and seizures, and headache. [WATCH TIME: 1 hour, 52 minutes]
The executive chair at the Rockefeller Neuroscience Institute at West Virginia University shed light on early data from a small sample of patients with early Alzheimer disease who underwent focused ultrasound treatment. [WATCH TIME: 5 minutes]
The Michael Hooker Distinguished Professor and director of the NIMH psychoactive drug screening program at University of North Carolina School of Medicine discussed the need for large placebo-controlled trials of psychedelics in migraine disorders. [WATCH TIME: 4 minutes]
The chief medical officer at Atara Biotherapeutics provided insight on the future direction of its investigational agent ATA188 following new data that suggested a link between Epstein-Barr virus and multiple sclerosis. [WATCH TIME: 4 minutes]
A panel of expert neurologists shares advice for community neurologists on preventive migraine treatment and exciting therapies to look forward to.
Episode 9 of the AUPN Leadership Minute features Donald S. Higgins, Jr., MD, of the Veterans Health Administration; and Douglas J. Gelb, MD, PhD, of the University of Michigan [WATCH TIME: 5 minutes]
Join Ahmed Obeidat, MD, PhD; Hesham Abboud, MD, PhD; and Rana K. Zabad, MD, FAAN, for perspectives on how the diagnostic criteria for multiple sclerosis have evolved over time.
The assistant professor of neurology at the University of Virginia spoke at the 2022 AES Conference about clinical outcomes of patients with dementia who experience seizures. [WATCH TIME: 5 minutes]
Experts provide a summary of the management of commonly encountered risk factors for secondary ischemic stroke and transient ischemic attack based on the newly published 2021 AHA/ASA recommendations.
Closing thoughts on advice to community neurologists treating spinal muscular atrophy (SMA).
Several therapies are progressing through the development pipeline and have shown promising data, setting up the multiple sclerosis treatment toolbox for possible expansion in coming years.
The neurologist from Cleveland Clinic discussed the importance of studying real-world outcomes in patients with migraine using CGRPs such as eptinezumab.